Protara Therapeutics (TARA) 10-Q3 Nov 232023 Q3 Quarterly reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2023	Nov. 01, 2023
Document Information Line Items
Entity Registrant Name	Protara Therapeutics, Inc.
Trading Symbol	TARA
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		11,364,903
Amendment Flag	false
Entity Central Index Key	0001359931
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-36694
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-4580525
Entity Address, Address Line One	345 Park Avenue South
Entity Address, Address Line Two	3rd Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10010
City Area Code	(646)
Local Phone Number	844-0337
Title of 12(b) Security	Common Stock, $0.001 par value per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 33,768	$ 24,127
Marketable debt securities	40,266	60,243
Prepaid expenses and other current assets	3,779	1,776
Total current assets	77,813	86,146
Restricted cash, non-current	745	745
Marketable debt securities, non-current		17,886
Property and equipment, net	1,401	1,592
Operating lease right-of-use asset	5,567	6,277
Other assets	2,941	644
Total assets	88,467	113,290
Current liabilities:
Accounts payable	2,504	1,586
Accrued expenses	3,305	3,237
Operating lease liability	966	917
Total current liabilities	6,775	5,740
Operating lease liability, non-current	4,736	5,467
Total liabilities	11,511	11,207
Commitments and contingencies (Note 8)
Stockholders’ Equity:
Preferred stock, $0.001 par value, authorized 10,000,000 shares: Series 1 Convertible Preferred Stock, 8,028 shares authorized at September 30, 2023 and December 31, 2022, 7,991 and 8,027 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively.
Common stock, $0.001 par value, authorized 100,000,000 shares: Common stock, 11,364,903 and 11,267,389 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively.	11	11
Additional paid-in capital	267,273	262,724
Accumulated deficit	(190,163)	(159,964)
Accumulated other comprehensive income (loss)	(165)	(688)
Total stockholders’ equity	76,956	102,083
Total liabilities and stockholders’ equity	$ 88,467	$ 113,290

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	11,364,903	11,267,389
Common stock, shares outstanding	11,364,903	11,267,389
Series 1 Convertible Preferred Stock
Preferred stock, shares authorized	8,028	8,028
Preferred stock, shares issued	7,991	8,027
Preferred stock, shares outstanding	7,991	8,027

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 6,218	$ 3,466	$ 18,608	$ 11,819
General and administrative	4,482	4,508	13,964	15,734
Total operating expenses	10,700	7,974	32,572	27,553
Loss from operations	(10,700)	(7,974)	(32,572)	(27,553)
Other income (expense), net:
Interest and investment income	840	283	2,373	568
Other income (expense), net	840	283	2,373	568
Net loss	$ (9,860)	$ (7,691)	$ (30,199)	$ (26,985)
Net loss per share attributable to common stockholders, basic and diluted (in Dollars per share)	$ (0.87)	$ (0.68)	$ (2.67)	$ (2.4)
Weighted-average shares outstanding, basic and diluted (in Shares)	11,347,887	11,265,475	11,320,027	11,256,995
Other comprehensive income (loss):
Net unrealized gain (loss) on marketable debt securities	$ 171	$ (8)	$ 523	$ (919)
Other comprehensive income (loss)	171	(8)	523	(919)
Comprehensive Loss	$ (9,689)	$ (7,699)	$ (29,676)	$ (27,904)

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net loss per share attributable to common stockholders, diluted	$ (0.87)	$ (0.68)	$ (2.67)	$ (2.40)
Weighted-average shares outstanding, diluted	11,347,887	11,265,475	11,320,027	11,256,995

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity - USD ($) $ in Thousands	Series 1 Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Total
Balance at Dec. 31, 2021		$ 11	$ 256,126	$ (94,012)	$ (211)	$ 161,914
Balance (in Shares) at Dec. 31, 2021	8,027	11,235,731
Settlement of restricted stock units			(72)			(72)
Settlement of restricted stock units (in Shares)		16,196
Stock-based compensation - restricted stock units			314			314
Stock-based compensation - stock options			1,565			1,565
Net Unrealized (loss) gain on marketable debt securities					(731)	(731)
Net loss				(10,755)		(10,755)
Balance at Mar. 31, 2022		$ 11	257,933	(104,767)	(942)	152,235
Balance (in Shares) at Mar. 31, 2022	8,027	11,251,927
Balance at Dec. 31, 2021		$ 11	256,126	(94,012)	(211)	161,914
Balance (in Shares) at Dec. 31, 2021	8,027	11,235,731
Net Unrealized (loss) gain on marketable debt securities						(919)
Net loss						(26,985)
Balance at Sep. 30, 2022		$ 11	261,294	(120,997)	(1,130)	139,178
Balance (in Shares) at Sep. 30, 2022	8,027	11,267,389
Balance at Mar. 31, 2022		$ 11	257,933	(104,767)	(942)	152,235
Balance (in Shares) at Mar. 31, 2022	8,027	11,251,927
Settlement of restricted stock units
Settlement of restricted stock units (in Shares)		5,250
Stock-based compensation - restricted stock units			390			390
Stock-based compensation - stock options			1,552			1,552
Net Unrealized (loss) gain on marketable debt securities					(180)	(180)
Net loss				(8,539)		(8,539)
Balance at Jun. 30, 2022		$ 11	259,875	(113,306)	(1,122)	145,458
Balance (in Shares) at Jun. 30, 2022	8,027	11,257,177
Settlement of restricted stock units			(18)			(18)
Settlement of restricted stock units (in Shares)		10,212
Stock-based compensation - restricted stock units			287			287
Stock-based compensation - stock options			1,150			1,150
Net Unrealized (loss) gain on marketable debt securities					(8)	(8)
Net loss				(7,691)		(7,691)
Balance at Sep. 30, 2022		$ 11	261,294	(120,997)	(1,130)	139,178
Balance (in Shares) at Sep. 30, 2022	8,027	11,267,389
Balance at Dec. 31, 2022		$ 11	262,724	(159,964)	(688)	102,083
Balance (in Shares) at Dec. 31, 2022	8,027	11,267,389
Settlement of restricted stock units			(64)			(64)
Settlement of restricted stock units (in Shares)		39,364
Stock-based compensation - restricted stock units			314			314
Stock-based compensation - stock options			1,261			1,261
Net Unrealized (loss) gain on marketable debt securities					219	219
Net loss				(9,045)		(9,045)
Balance at Mar. 31, 2023		$ 11	264,235	(169,009)	(469)	94,768
Balance (in Shares) at Mar. 31, 2023	8,027	11,306,753
Balance at Dec. 31, 2022		$ 11	262,724	(159,964)	(688)	102,083
Balance (in Shares) at Dec. 31, 2022	8,027	11,267,389
Net Unrealized (loss) gain on marketable debt securities						523
Net loss						(30,199)
Balance at Sep. 30, 2023		$ 11	267,273	(190,163)	(165)	76,956
Balance (in Shares) at Sep. 30, 2023	7,991	11,364,903
Balance at Mar. 31, 2023		$ 11	264,235	(169,009)	(469)	94,768
Balance (in Shares) at Mar. 31, 2023	8,027	11,306,753
Settlement of restricted stock units
Settlement of restricted stock units (in Shares)		1,209
Stock-based compensation - restricted stock units			326			326
Stock-based compensation - stock options			1,292			1,292
Net Unrealized (loss) gain on marketable debt securities					133	133
Net loss				(11,294)		(11,294)
Balance at Jun. 30, 2023		$ 11	265,853	(180,303)	(336)	85,225
Balance (in Shares) at Jun. 30, 2023	8,027	11,307,962
Settlement of restricted stock units			(27)			(27)
Settlement of restricted stock units (in Shares)		21,118
Conversion of Series 1 Convertible Preferred Stock to Common Stock
Conversion of Series 1 Convertible Preferred Stock to Common Stock (in Shares)	(36)	35,823
Stock-based compensation - restricted stock units			275			275
Stock-based compensation - stock options			1,172			1,172
Net Unrealized (loss) gain on marketable debt securities					171	171
Net loss				(9,860)		(9,860)
Balance at Sep. 30, 2023		$ 11	$ 267,273	$ (190,163)	$ (165)	$ 76,956
Balance (in Shares) at Sep. 30, 2023	7,991	11,364,903

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Cash flows used in operating activities:
Net loss	$ (9,860)	$ (7,691)	$ (30,199)	$ (26,985)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation			4,640	5,258
Operating lease right-of-use asset			711	1,024
Depreciation			234	173
Amortization of premium (Accretion of discount) on marketable debt securities			(331)	1,029
Changes in operating assets and liabilities:
Prepaid expenses and other current assets			(1,919)	(433)
Other assets			(2,297)	131
Accounts payable			918	(498)
Accrued expenses			68	(135)
Operating lease liabilities			(682)	(995)
Net cash used in operating activities			(28,857)	(21,431)
Cash flows from investing activities:
Purchase of marketable debt securities			(12,186)	(14,428)
Proceeds from maturity and redemption of marketable debt securities			50,820	47,837
Purchase of property and equipment			(45)	(114)
Net cash provided by investing activities			38,589	33,295
Cash flows from financing activities:
Repurchase of shares in connection with settlement of RSUs			(91)	(90)
Net cash used in financing activities			(91)	(90)
Net increase (decrease) in cash and cash equivalents and restricted cash			9,641	11,774
Cash and cash equivalents and restricted cash - beginning of year			24,872	36,469
Cash and cash equivalents and restricted cash - end of period	34,513	48,243	34,513	48,243
Reconciliation of cash and cash equivalents and restricted cash to the condensed consolidated balance sheets:
Cash and cash equivalents	33,768	47,498	33,768	47,498
Restricted cash, non-current	745	745	745	745
Cash and cash equivalents and restricted cash	$ 34,513	$ 48,243	$ 34,513	$ 48,243

Organization and Nature of the

Organization and Nature of the Business	9 Months Ended
Organization and Nature of the Business	Sep. 30, 2023
Organization and Nature of the Business [Abstract]
Organization and Nature of the Business	1. Organization and Nature of the Business Overview Protara Therapeutics, Inc., and its consolidated subsidiaries (“Protara” or the “Company”), is a clinical-stage biopharmaceutical company committed to advancing transformative therapies for the treatment of cancer and rare diseases. Protara’s portfolio includes two development programs utilizing TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer, or NMIBC and lymphatic malformations, or LMs. The third program in the portfolio is Intravenous, or IV, Choline Chloride, an investigational phospholipid substrate replacement therapy in development for patients receiving parenteral nutrition, or PN. Liquidity, Capital Resources and Management Plans The Company is in the business of developing biopharmaceuticals and has no current or near-term revenues. The Company has incurred substantial clinical and other costs in its drug development efforts. The Company will need to raise additional capital in order to fully realize management’s plans. The Company believes that its current financial resources are sufficient to satisfy the Company’s estimated liquidity needs for at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements. Impact of the COVID-19 Pandemic As a result of the impacts of the COVID-19 pandemic, the Company has experienced delays and, should another global pandemic or other public health crisis occur, may experience additional future delays that impact the business, research and development activities, the healthcare systems in which the Company operates and the global economy as a whole. The Company will continue to monitor the long-term consequences of the COVID-19 pandemic and its related macroeconomic effects closely including whether the effects would have a material impact on the Company’s operations, liquidity and capital resources.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2023
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the United States Securities and Exchange Commission, or SEC, on March 8, 2023. Except as reflected below, there were no changes to the Company’s significant accounting policies as described in the Annual Report on Form 10-K. Reflected in this note are updates to accounting policies, including the impact of the adoption of new policies. Basis of Presentation The accompanying condensed consolidated financial statements and the related disclosures as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022 are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, and the rules and regulations of the SEC for interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim condensed consolidated financial statements should be read in conjunction with the 2022 and 2021 audited consolidated financial statements and notes included in the Annual Report on Form 10-K. The December 31, 2022 consolidated balance sheet included herein was derived from the audited financial statements as of that date but does not include all disclosures including notes required by U.S. GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company’s financial position and results of operations for the three and nine months ended September 30, 2023 and 2022. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or any other interim period or future year or period. Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in the accompanying condensed consolidated financial statements. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Significant items subject to such estimates include but are not limited to accrued research and development expenses, income taxes, the valuation of deferred tax assets, and contingencies. On an ongoing basis, the Company’s management evaluates its estimates based on historical and anticipated results, trends, and various other assumptions believed to be reasonable. Actual results could differ from those estimates. The results of any changes in accounting estimates are reflected in the financial statements of the period in which the change becomes evident. Concentrations of Credit Risk Financial instruments, which potentially subject the Company to concentrations of credit risk, consists principally of cash, cash equivalents and investments in marketable debt securities. The Company currently invests its excess cash primarily in money market funds and high quality investment grade marketable debt securities of corporations. The Company has adopted an investment policy that includes guidelines relative to credit quality, diversification and maturities to preserve principal and liquidity. Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board, or the FASB, issued ASU 2016-13 - Measurement of Credit Losses on Financial Statements Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates Recent Accounting Pronouncements Not Yet Adopted The Company has evaluated other recently issued accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption. Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were available to be issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
Fair Value of Financial Instruments	Sep. 30, 2023
Fair Value of Financial Instruments [Abstract]
Fair Value of Financial Instruments	3. Fair Value of Financial Instruments The Company measures certain financial assets and liabilities at fair value. Fair value is determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as determined by either the principal market or the most advantageous market. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy, as follows: ● Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. ● Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. ● Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. The following tables present the Company’s financial assets and liabilities that are measured and carried at fair value and indicate the level within the fair value hierarchy of valuation techniques it utilizes to determine such fair value: September 30, 2023 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds (a) $ 33,213 $ - $ - $ 33,213 Restricted cash, non-current: Money market funds (b) 745 - - 745 Marketable debt securities: Corporate bonds (c) - 40,266 - 40,266 Total $ 33,958 $ 40,266 $ - $ 74,224 December 31, 2022 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds (a) $ 13,284 $ - $ - $ 13,284 Corporate bonds (a) - 2,523 - 2,523 Restricted cash, non-current: Money market funds (b) 745 - - 745 Marketable debt securities: Corporate bonds (c) - 78,129 - 78,129 Total $ 14,029 $ 80,652 $ - $ 94,681 (a) Money market funds and corporate debt securities with original maturities of 90 days or less are included within Cash and cash equivalents in the condensed consolidated balance sheets. (b) Restricted Money market funds are included within Restricted Cash, non-current in the condensed consolidated balance sheets. (c) Corporate debt securities with original maturities greater than 90 days are included within Marketable securities in the condensed consolidated balance sheets and classified as current or noncurrent based upon whether the maturity of the financial asset is less than or greater than 12 months. Money market funds are classified as Level 1 within the fair value hierarchy, because they are valued using quoted prices in active markets. Corporate debt securities classified as Level 2 within the fair value hierarchy are valued on the basis of prices from an orderly transaction between market participants provided by reputable dealers or pricing services. Prices of these securities are obtained through independent, third-party pricing services and include market quotations that may include both observable and unobservable inputs. In determining the value of a particular investment, pricing services may use certain information with respect to transactions in such investments, quotations from dealers, pricing matrices and market transactions in comparable investments and various relationships between investments. There were no transfers of financial instruments among Level 1, Level 2, and Level 3 during the period presented. Cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses at September 30, 2023 and December 31, 2022 are carried at amounts that approximate fair value due to their short-term maturities.

Marketable Debt Securities

Marketable Debt Securities	9 Months Ended
Marketable Debt Securities	Sep. 30, 2023
Marketable Debt Securities [Abstract]
Marketable Debt Securities	4. Marketable Debt Securities Marketable debt securities, all of which were classified as available-for-sale, consist of the following: September 30, 2023 Amortized Unrealized Unrealized (a) Estimated Corporate bonds - presented in marketable debt securities $ 40,431 $ - $ (165 ) $ 40,266 Total $ 40,431 $ - $ (165 ) $ 40,266 (a) The unrealized loss of $165 is comprised of bonds with losses sustained for greater than 12 months of $77 and of bonds with losses sustained for less than 12 months of $88. December 31, 2022 Amortized Unrealized Unrealized Estimated Corporate bonds - presented in marketable debt securities $ 60,790 $ - $ (547 ) $ 60,243 Corporate bonds - presented in marketable debt securities, non-current 18,027 - (141 ) 17,886 Total $ 78,817 $ - $ (688 ) $ 78,129 The Company has recorded the securities at fair value in its condensed consolidated balance sheets and unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss). The amount of realized gains and losses reclassified into earnings are based on the specific identification of the securities sold or securities that reached maturity date. The amount of realized gains and losses reclassified into earnings have not been material to the Company’s condensed consolidated statements of operations and comprehensive loss. At the time of purchase, the Company determines the appropriate classification of investments based upon its intent with regard to such investments. The Company classifies investments in marketable debt securities with remaining maturities when purchased of greater than three months as available-for-sale. Investments with a remaining maturity date greater than one year are classified as non-current. The contractual maturities of all securities held at September 30, 2023 was 7 months or less. There were no sales of securities in the periods presented. The Company periodically evaluates the need for an allowance for credit losses. This evaluation includes consideration of several qualitative and quantitative factors, including whether it plans to sell the security, whether it is more likely than not it will be required to sell any marketable debt securities before recovery of its amortized cost basis, and if the entity has the ability and intent to hold the security to maturity, and the portion of any unrealized loss that is the result of a credit loss. Factors considered in making these evaluations include quoted market prices, recent financial results, operating trends, and implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, expected cash flows from securities, other publicly available information that may affect the value of the marketable debt security, duration and severity of decline in value and the Company’s strategy and intentions for holding the marketable debt security. Securities with an amortized cost basis in excess of estimated fair value are assessed to determine what amount of the excess, if any, is caused by expected credit losses. For the period ended September 30, 2023, it was determined that none Investment Income Investment income consists of the following: For the For the 2023 2022 2023 2022 Interest income $ 710 $ 557 $ 2,025 $ 1,598 Dividend income 2 - 6 - Accretion of discount (amortization of premium), net 128 (274 ) 342 (1,030 ) Total interest and investment income $ 840 $ 283 $ 2,373 $ 568

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
Prepaid Expenses and Other Current Assets	Sep. 30, 2023
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	5. Prepaid Expenses and Other Current Assets Included in the Company’s prepaid expenses and other current assets within the condensed consolidated balance sheets are: As of September 30, December 31, Prepaid insurance $ 374 $ 288 Prepaid research and development 2,914 569 Prepaid software 80 122 Accrued interest on marketable debt securities 279 486 Other prepaid expenses 130 184 Other current assets 2 127 Total $ 3,779 $ 1,776

Accrued Expenses

Accrued Expenses	9 Months Ended
Accrued Expenses	Sep. 30, 2023
Accrued Expenses [Abstract]
Accrued Expenses	6. Accrued Expenses Included in the Company’s accrued expenses within the condensed consolidated balance sheets are: As of September 30, December 31, Employee costs $ 1,513 $ 2,543 Research and development costs 1,711 512 Other expenses 81 182 Total $ 3,305 $ 3,237

Leases

Leases	9 Months Ended
Leases	Sep. 30, 2023
Leases [Abstract]
Leases	7. Leases Operating leases Leases classified as operating leases are included in operating lease right-of use, or ROU, assets, operating lease liabilities and operating lease liabilities, non-current, in the Company’s condensed consolidated balance sheets. Cash paid for operating lease liabilities was $995 during each of the nine months ended September 30, 2023 and 2022. The components of lease expense were as follows: For the Three Months Ended For the Nine Months Ended Lease cost 2023 2022 2023 2022 Operating lease cost $ 341 $ 342 $ 1,024 $ 1,024 Short-term lease cost - - - 3 Total $ 341 $ 342 $ 1,024 $ 1,027 Variable lease expense for the three and nine months ended September 30, 2023 and 2022, respectively, was not material. The weighted-average remaining lease term and the weighted average discount rate for operating leases were: As of Weighted-average discount rate 7.0 % Weighted-average remaining lease term – operating lease (in months) 58 As of September 30, 2023, the expected annual minimum lease payments of the Company’s operating lease liabilities were as follows: For Years Ending December 31, Operating 2023 (excluding the nine months ended September 30, 2023) $ 332 2024 1,327 2025 1,395 2026 1,429 2027 1,429 Thereafter 805 Total operating lease payments 6,717 Less: imputed interest 1,015 Present value of future minimum lease payments $ 5,702

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2023
Commitments and Contingencies [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Commitments The Company has commitments under certain license and collaboration agreements, lease agreements, and employment agreements. Commitments under certain license agreements primarily include annual payments, payments upon the achievement of certain milestones, and royalty payments based on net sales of licensed products. Commitments under lease agreements consist of future minimum lease payments for operating leases which are further described in Note 7 of this Quarterly Report on Form 10-Q. Contingencies From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Management is of the opinion that the ultimate outcome of these matters would not have a material adverse impact on the financial position of the Company or the results of its operations. In the normal course of business, the Company enters into contracts in which it makes representations and warranties regarding the performance of its services and that its services will not infringe on third-party intellectual rights. There have been no significant events related to such representations and warranties in which the Company believes the outcome could result in losses or penalties in the future.

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
Stockholders’ Equity	Sep. 30, 2023
Stockholders’ Equity [Abstract]
Stockholders’ Equity	9 Stockholders’ Equity Common Stock As of September 30, 2023 and December 31, 2022, the Company had 100,000,000 shares of common stock authorized for issuance, $0.001 par value per share, of which 11,364,903 and 11,267,389 shares were issued and outstanding, respectively. The holders of the Company’s common stock are entitled to one vote per share. Preferred Stock As of September 30, 2023 and December 31, 2022, the Company had 10,000,000 shares of preferred stock authorized for issuance, $0.001 par value per share, of which 8,028 shares of Series 1 Convertible Preferred Stock were authorized for issuance and 7,991 and 8,027 shares were issued and outstanding as of September 30, 2023 and December 31, 2022, respectively. Each share of Series 1 Convertible Preferred Stock is convertible into approximately 1,000 shares of common stock, at a conversion price initially equal to approximately $7.01 per common share, subject to certain adjustments as described in the certificate of designation of preferences, rights and limitations of Series 1 Convertible Preferred Stock. During August 2023, approximately 36 shares of Series 1 Convertible Preferred Stock were converted into 35,823 shares of common stock. The holders of Series 1 Convertible Preferred Stock are not entitled to vote.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
Stock-Based Compensation	Sep. 30, 2023
Stock-Based Compensation [Abstract]
Stock-Based Compensation	10 Stock-Based Compensation 2020 Inducement Plan On March 26, 2020, the Compensation Committee of the Board of Directors (the “Compensation Committee”) approved the 2020 Inducement Plan in order to award nonstatutory stock options, restricted stock awards, restricted stock unit awards and other stock-based awards to persons not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company. The 2020 Inducement Plan provides for a total of 600,000 shares for the issuance of the Company’s common stock. The Compensation Committee also adopted a form of stock option grant notice and stock option agreement and forms of restricted stock unit grant notice and restricted stock unit agreement for use with the Inducement Plan. As of September 30, 2023, 160,625 shares remain available to be issued under the 2020 Inducement Plan. 2017 Equity Incentive Plan On August 10, 2017, Private ArTara (a predecessor entity of the Company), its Board of Directors and its stockholders approved the ArTara Therapeutics, Inc. 2017 Equity Incentive Plan to enable Private ArTara and its affiliates to recruit and retain highly qualified personnel and to incentivize personnel for productivity and growth. The 2017 Equity Incentive Plan provided for the grant of a total of 2,000,000 shares for the issuance of stock options, stock appreciation rights, restricted stock and restricted stock units to among others, members of the Board of Directors, employees, consultants and service providers to the Company and its affiliates. As of January 9, 2020, no additional awards will be made under the 2017 Equity Incentive Plan. 2014 Equity Incentive Plan On October 3, 2014, the stockholders approved the 2014 Equity Incentive Plan. On June 20, 2017, the Company’s Board of Directors amended the 2014 Equity Incentive Plan, or the Amended 2014 Plan. On July 31, 2017, the stockholders approved this amendment. On January 1, 2020, Protara Therapeutics, Inc. amended its Amended and Restated 2014 Equity Incentive Plan. The Amended and Restated 2014 Plan, as amended, provides for the grant of incentive and non-statutory stock options, stock appreciation rights, restricted stock and stock unit awards, performance units, stock grants and qualified performance-based awards. The Amended and Restated 2014 Plan, as amended, provides that the number of shares reserved and available for issuance will automatically increase each January 1, by four percent of the Company’s common stock on the immediately preceding December 31, adjusted for the number of shares of the Company’s common stock issuable upon conversion of any security that the Company may issue that is convertible into or exchangeable for the Company’s common stock, or such lesser number of shares as determined by the Company’s Board of Directors. On January 1, 2023, pursuant to the annual evergreen feature of the Amended and Restated 2014 Plan, as amended, the number of shares authorized under the Amended and Restated 2014 Plan, as amended, was increased by 861,933 shares to 3,563,303 shares. As of September 30, 2023, 544,137 shares remain available to be issued under the Amended and Restated 2014 Plan, as amended. Terms of the stock awards, including vesting requirements, are determined by the Board of Directors, subject to the provisions of the plans. Certain awards provide for accelerated vesting if there is a change in control as defined in the plan. 2014 Employee Stock Purchase Plan On October 3, 2014, the stockholders approved the 2014 Employee Stock Purchase Plan, or the 2014 ESPP. The 2014 ESPP initially authorized the issuance of up to 3,513 shares of the Company’s common stock. The number of shares increases each January 1, commencing on January 1, 2015 and ending on (and including) January 1, 2024, by an amount equal to the lesser of one percent of the outstanding shares as of the end of the immediately preceding fiscal year, 7,025 shares or any lower amount determined by the Company’s Board of Directors prior to each such January 1st. On January 1, 2023, pursuant to the increase per the 2014 ESPP, the number of shares authorized under the 2014 ESPP was increased by 7,025 shares to 39,087 shares. As of September 30, 2023, the authorized number of shares under the 2014 ESPP was 39,087 and the number of shares available for issuance was 39,087. During the nine months ended September 30, 2023 and 2022, no shares were issued under the 2014 ESPP. Restricted Stock Units The following table summarizes restricted stock unit, or RSU, activities for the nine months ended September 30, 2023: Restricted Weighted Non-vested as of December 31, 2022 196,838 $ 12.49 Granted 165,100 3.02 Forfeited (30,431 ) 4.36 Vested (94,528 ) 12.16 Non-vested as of September 30, 2023 236,979 $ 7.07 The fair value of RSUs is amortized on a straight-line basis over the requisite service period of the respective awards. As of September 30, 2023, the unamortized value of RSUs was $863. As of September 30, 2023, the weighted average remaining amortization period was 1.8 years. As of September 30, 2023 and December 31, 2022, 289,500 RSUs have vested that have not yet been settled into shares of the Company’s common stock. During the nine months ended September 30, 2023, the Company issued 61,691 shares of the Company’s common stock from the net settlement of 94,528 RSUs. The Company paid $91 in connection with the net share settlement of these RSUs. Stock Options The following table summarizes stock option activities for the nine months ended September 30, 2023: Options Weighted Weighted Aggregate Outstanding as of December 31, 2022 1,828,329 $ 14.23 8.16 $ - Granted 1,267,900 3.04 - - Exercised - - - - Forfeited (153,650 ) 6.93 - - Expired (9,054 ) 14.39 - - Outstanding as of September 30, 2023 2,933,525 $ 9.77 8.05 $ - Vested and expected to vest at September 30, 2023 2,933,525 $ 9.77 8.05 $ - Exercisable as of September 30, 2023 1,198,035 15.93 6.81 - The weighted average grant date fair value per share of the options granted during the nine months ended September 30, 2023 and 2022 was $2.40 and $5.04, respectively. As of September 30, 2023, there was approximately $6,819 of unrecognized share-based compensation for unvested stock option grants, which is expected to be recognized over a weighted average period of 2.73 years. The total unrecognized stock-based compensation cost will be adjusted for actual forfeitures as they occur. Summary of Stock-Based Compensation Expense The following tables summarize total stock-based compensation costs recognized: For the Three Months Ended For the Nine Months Ended 2023 2022 2023 2022 Restricted stock units $ 275 $ 287 $ 915 $ 991 Stock options 1,172 1,150 3,725 4,267 Total $ 1,447 $ 1,437 $ 4,640 $ 5,258 Stock-based compensation expense was reflected within the condensed consolidated statements of operations and comprehensive loss as: For the Three Months Ended For the Nine Months Ended 2023 2022 2023 2022 Research and development $ 419 $ 361 $ 1,233 $ 1,150 General and administrative 1,028 1,076 3,407 4,108 Total $ 1,447 $ 1,437 $ 4,640 $ 5,258

Net Loss Per Common Share

Net Loss Per Common Share	9 Months Ended
Net Loss Per Common Share	Sep. 30, 2023
Net Loss Per Common Share [Abstract]
Net Loss per Common Share	11. Net Loss per Common Share The following table sets forth the computation of the net loss per share attributable to common stockholders, basic and diluted: For the Three Months Ended For the Nine Months Ended 2023 2022 2023 2022 Numerator: Net loss attributable to common stockholders $ (9,860 ) $ (7,691 ) $ (30,199 ) $ (26,985 ) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 11,347,887 11,265,475 11,320,027 11,256,995 Net loss per share attributable to common stockholders, basic and diluted (0.87 ) (0.68 ) $ (2.67 ) $ (2.40 ) Since the Company was in a net loss position for all periods presented, net loss per share attributable to common stockholders was the same, on a basic and diluted basis, as the inclusion of all potential common equivalent shares outstanding would have been anti-dilutive. The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: As of 2023 2022 Stock options issued and outstanding 2,933,525 1,862,358 Restricted stock units issued and outstanding 526,479 493,938 Conversion of Series 1 Convertible Preferred Stock 7,993,217 8,029,039 Total potentially dilutive shares 11,453,221 10,385,335

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
Accounting Policies, by Policy (Policies)	Sep. 30, 2023
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements and the related disclosures as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022 are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, and the rules and regulations of the SEC for interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim condensed consolidated financial statements should be read in conjunction with the 2022 and 2021 audited consolidated financial statements and notes included in the Annual Report on Form 10-K. The December 31, 2022 consolidated balance sheet included herein was derived from the audited financial statements as of that date but does not include all disclosures including notes required by U.S. GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company’s financial position and results of operations for the three and nine months ended September 30, 2023 and 2022. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or any other interim period or future year or period.
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in the accompanying condensed consolidated financial statements.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Significant items subject to such estimates include but are not limited to accrued research and development expenses, income taxes, the valuation of deferred tax assets, and contingencies. On an ongoing basis, the Company’s management evaluates its estimates based on historical and anticipated results, trends, and various other assumptions believed to be reasonable. Actual results could differ from those estimates. The results of any changes in accounting estimates are reflected in the financial statements of the period in which the change becomes evident.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments, which potentially subject the Company to concentrations of credit risk, consists principally of cash, cash equivalents and investments in marketable debt securities. The Company currently invests its excess cash primarily in money market funds and high quality investment grade marketable debt securities of corporations. The Company has adopted an investment policy that includes guidelines relative to credit quality, diversification and maturities to preserve principal and liquidity.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board, or the FASB, issued ASU 2016-13 - Measurement of Credit Losses on Financial Statements Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates
Recent Accounting Pronouncements Not Yet Adopted	Recent Accounting Pronouncements Not Yet Adopted The Company has evaluated other recently issued accounting pronouncements and has concluded that the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.
Subsequent Events	Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were available to be issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
Fair Value of Financial Instruments (Tables)	Sep. 30, 2023
Fair Value of Financial Instruments [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables present the Company’s financial assets and liabilities that are measured and carried at fair value and indicate the level within the fair value hierarchy of valuation techniques it utilizes to determine such fair value: September 30, 2023 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds (a) $ 33,213 $ - $ - $ 33,213 Restricted cash, non-current: Money market funds (b) 745 - - 745 Marketable debt securities: Corporate bonds (c) - 40,266 - 40,266 Total $ 33,958 $ 40,266 $ - $ 74,224 December 31, 2022 Level 1 Level 2 Level 3 Total Cash equivalents: Money market funds (a) $ 13,284 $ - $ - $ 13,284 Corporate bonds (a) - 2,523 - 2,523 Restricted cash, non-current: Money market funds (b) 745 - - 745 Marketable debt securities: Corporate bonds (c) - 78,129 - 78,129 Total $ 14,029 $ 80,652 $ - $ 94,681 (a) Money market funds and corporate debt securities with original maturities of 90 days or less are included within Cash and cash equivalents in the condensed consolidated balance sheets. (b) Restricted Money market funds are included within Restricted Cash, non-current in the condensed consolidated balance sheets. (c) Corporate debt securities with original maturities greater than 90 days are included within Marketable securities in the condensed consolidated balance sheets and classified as current or noncurrent based upon whether the maturity of the financial asset is less than or greater than 12 months.

Marketable Debt Securities (Tab

Marketable Debt Securities (Tables)	9 Months Ended
Marketable Debt Securities (Tables)	Sep. 30, 2023
Marketable Debt Securities [Abstract]
Schedule of Marketable Debt Securities	Marketable debt securities, all of which were classified as available-for-sale, consist of the following: September 30, 2023 Amortized Unrealized Unrealized (a) Estimated Corporate bonds - presented in marketable debt securities $ 40,431 $ - $ (165 ) $ 40,266 Total $ 40,431 $ - $ (165 ) $ 40,266 December 31, 2022 Amortized Unrealized Unrealized Estimated Corporate bonds - presented in marketable debt securities $ 60,790 $ - $ (547 ) $ 60,243 Corporate bonds - presented in marketable debt securities, non-current 18,027 - (141 ) 17,886 Total $ 78,817 $ - $ (688 ) $ 78,129
Schedule of Interest and Investment Income	Investment income consists of the following: For the For the 2023 2022 2023 2022 Interest income $ 710 $ 557 $ 2,025 $ 1,598 Dividend income 2 - 6 - Accretion of discount (amortization of premium), net 128 (274 ) 342 (1,030 ) Total interest and investment income $ 840 $ 283 $ 2,373 $ 568

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
Prepaid Expenses and Other Current Assets (Tables)	Sep. 30, 2023
Prepaid Expenses and Other Current Assets [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Included in the Company’s prepaid expenses and other current assets within the condensed consolidated balance sheets are: As of September 30, December 31, Prepaid insurance $ 374 $ 288 Prepaid research and development 2,914 569 Prepaid software 80 122 Accrued interest on marketable debt securities 279 486 Other prepaid expenses 130 184 Other current assets 2 127 Total $ 3,779 $ 1,776

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
Accrued Expenses (Tables)	Sep. 30, 2023
Accrued Expenses [Abstract]
Schedule of Accrued Expenses	Included in the Company’s accrued expenses within the condensed consolidated balance sheets are: As of September 30, December 31, Employee costs $ 1,513 $ 2,543 Research and development costs 1,711 512 Other expenses 81 182 Total $ 3,305 $ 3,237

Leases (Tables)

Leases (Tables)	9 Months Ended
Leases (Tables)	Sep. 30, 2023
Leases [Abstract]
Schedule of Lease Expense	The components of lease expense were as follows: For the Three Months Ended For the Nine Months Ended Lease cost 2023 2022 2023 2022 Operating lease cost $ 341 $ 342 $ 1,024 $ 1,024 Short-term lease cost - - - 3 Total $ 341 $ 342 $ 1,024 $ 1,027
Schedule of Weighted Average Remaining Lease Term and the Weighted Average Discount Rate for Operating Leases	The weighted-average remaining lease term and the weighted average discount rate for operating leases were: As of Weighted-average discount rate 7.0 % Weighted-average remaining lease term – operating lease (in months) 58
Schedule of Annual Minimum Lease Payments	As of September 30, 2023, the expected annual minimum lease payments of the Company’s operating lease liabilities were as follows: For Years Ending December 31, Operating 2023 (excluding the nine months ended September 30, 2023) $ 332 2024 1,327 2025 1,395 2026 1,429 2027 1,429 Thereafter 805 Total operating lease payments 6,717 Less: imputed interest 1,015 Present value of future minimum lease payments $ 5,702

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
Stock-Based Compensation (Tables)	Sep. 30, 2023
Stock-Based Compensation [Abstract]
Schedule of Restricted Stock Unit	The following table summarizes restricted stock unit, or RSU, activities for the nine months ended September 30, 2023: Restricted Weighted Non-vested as of December 31, 2022 196,838 $ 12.49 Granted 165,100 3.02 Forfeited (30,431 ) 4.36 Vested (94,528 ) 12.16 Non-vested as of September 30, 2023 236,979 $ 7.07
Schedule of Stock Option Activities	The following table summarizes stock option activities for the nine months ended September 30, 2023: Options Weighted Weighted Aggregate Outstanding as of December 31, 2022 1,828,329 $ 14.23 8.16 $ - Granted 1,267,900 3.04 - - Exercised - - - - Forfeited (153,650 ) 6.93 - - Expired (9,054 ) 14.39 - - Outstanding as of September 30, 2023 2,933,525 $ 9.77 8.05 $ - Vested and expected to vest at September 30, 2023 2,933,525 $ 9.77 8.05 $ - Exercisable as of September 30, 2023 1,198,035 15.93 6.81 -
Schedule of Total Stock Based Compensation Costs	The following tables summarize total stock-based compensation costs recognized: For the Three Months Ended For the Nine Months Ended 2023 2022 2023 2022 Restricted stock units $ 275 $ 287 $ 915 $ 991 Stock options 1,172 1,150 3,725 4,267 Total $ 1,447 $ 1,437 $ 4,640 $ 5,258
Stock-based compensation expense was reflected within the condensed consolidated statements of operations and comprehensive loss as:	Stock-based compensation expense was reflected within the condensed consolidated statements of operations and comprehensive loss as: For the Three Months Ended For the Nine Months Ended 2023 2022 2023 2022 Research and development $ 419 $ 361 $ 1,233 $ 1,150 General and administrative 1,028 1,076 3,407 4,108 Total $ 1,447 $ 1,437 $ 4,640 $ 5,258

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	9 Months Ended
Net Loss Per Common Share (Tables)	Sep. 30, 2023
Net Loss Per Common Share [Abstract]
Schedule of Net Loss Per Share Attributable to Common Stockholders, Basic and Diluted	The following table sets forth the computation of the net loss per share attributable to common stockholders, basic and diluted: For the Three Months Ended For the Nine Months Ended 2023 2022 2023 2022 Numerator: Net loss attributable to common stockholders $ (9,860 ) $ (7,691 ) $ (30,199 ) $ (26,985 ) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 11,347,887 11,265,475 11,320,027 11,256,995 Net loss per share attributable to common stockholders, basic and diluted (0.87 ) (0.68 ) $ (2.67 ) $ (2.40 )
Schedule of Weighted Average Dilutive Common Shares	The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: As of 2023 2022 Stock options issued and outstanding 2,933,525 1,862,358 Restricted stock units issued and outstanding 526,479 493,938 Conversion of Series 1 Convertible Preferred Stock 7,993,217 8,029,039 Total potentially dilutive shares 11,453,221 10,385,335

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details) - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - USD ($) $ in Thousands		Sep. 30, 2023	Dec. 31, 2022
Cash equivalents:
Money market funds	[1]	$ 33,213	$ 13,284
Corporate bonds	[1]		2,523
Restricted cash, non-current:
Money market funds	[2]	745	745
Marketable debt securities:
Corporate bonds	[3]	40,266	78,129
Total		74,224	94,681
Level 1 [Member]
Cash equivalents:
Money market funds	[1]	33,213	13,284
Corporate bonds	[1]
Restricted cash, non-current:
Money market funds	[2]	745	745
Marketable debt securities:
Corporate bonds	[3]
Total		33,958	14,029
Level 2 [Member]
Cash equivalents:
Money market funds	[1]
Corporate bonds	[1]		2,523
Restricted cash, non-current:
Money market funds	[2]
Marketable debt securities:
Corporate bonds	[3]	40,266	78,129
Total		40,266	80,652
Level 3 [Member]
Cash equivalents:
Money market funds	[1]
Corporate bonds	[1]
Restricted cash, non-current:
Money market funds	[2]
Marketable debt securities:
Corporate bonds	[3]
Total

[1] Money market funds and corporate debt securities with original maturities of 90 days or less are included within Cash and cash equivalents in the condensed consolidated balance sheets. Restricted Money market funds are included within Restricted Cash, non-current in the condensed consolidated balance sheets. Corporate debt securities with original maturities greater than 90 days are included within Marketable securities in the condensed consolidated balance sheets and classified as current or noncurrent based upon whether the maturity of the financial asset is less than or greater than 12 months.

Marketable Debt Securities (Det

Marketable Debt Securities (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Marketable Debt Securities [Abstract]
Unrealized loss	$ 165
Unrealized loss sustained for greater than 12 months	77
Unrealized loss sustained for less than 12 months	88
Unrealized loss is related to expected credit losses

Marketable Debt Securities (D_2

Marketable Debt Securities (Details) - Schedule of Marketable Debt Securities - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Marketable Debt Securities [Line Items]
Amortized Cost	$ 40,431	$ 78,817
Unrealized Gains
Unrealized Losses	(165)	(688)
Estimated Fair Value	40,266	78,129
Corporate bonds - presented in marketable debt securities [Member]
Marketable Debt Securities [Line Items]
Amortized Cost	40,431	60,790
Unrealized Gains
Unrealized Losses	(165)	(547)
Estimated Fair Value	$ 40,266	60,243
Corporate bonds - presented in marketable debt securities, non-current [Member]
Marketable Debt Securities [Line Items]
Amortized Cost		18,027
Unrealized Gains
Unrealized Losses		(141)
Estimated Fair Value		$ 17,886

Marketable Debt Securities (D_3

Marketable Debt Securities (Details) - Schedule of Interest and Investment Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Marketable Debt Securities [Abstract]
Interest income	$ 710	$ 557	$ 2,025	$ 1,598
Dividend income	2		6
Accretion of discount (amortization of premium), net	128	(274)	342	(1,030)
Total interest and investment income	$ 840	$ 283	$ 2,373	$ 568

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid insurance	$ 374	$ 288
Prepaid research and development	2,914	569
Prepaid software	80	122
Accrued interest on marketable debt securities	279	486
Other prepaid expenses	130	184
Other current assets	2	127
Total	$ 3,779	$ 1,776

Accrued Expenses (Details) - Sc

Accrued Expenses (Details) - Schedule of Accrued Expenses - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Schedule Of Accrued Expenses [Abstract]
Employee costs	$ 1,513	$ 2,543
Research and development costs	1,711	512
Other expenses	81	182
Total	$ 3,305	$ 3,237

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	9 Months Ended
Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Sep. 30, 2022
Leases [Abstract]
Cash paid for operating lease liabilities	$ 995	$ 995

Leases (Details) - Schedule of

Leases (Details) - Schedule of Lease Expense - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Schedule of Lease Expense [Abstract]
Operating lease cost	$ 341	$ 342	$ 1,024	$ 1,024
Short-term lease cost				3
Total	$ 341	$ 342	$ 1,024	$ 1,027

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Weighted Average Remaining Lease Term and the Weighted Average Discount Rate for Operating Leases	Sep. 30, 2023
Schedule of Other Information Related to Leases [Abstract]
Weighted-average discount rate	7%
Weighted-average remaining lease term – operating lease (in months)	58 months

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of Annual Minimum Lease Payments $ in Thousands	Sep. 30, 2023 USD ($)
Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
2023 (excluding the nine months ended September 30, 2023)	$ 332
2024	1,327
2025	1,395
2026	1,429
2027	1,429
Thereafter	805
Total operating lease payments	6,717
Less: imputed interest	1,015
Present value of future minimum lease payments	$ 5,702

Stockholders_ Equity (Details)

Stockholders’ Equity (Details)	9 Months Ended
Stockholders’ Equity (Details)	Sep. 30, 2023 $ / shares shares	Dec. 31, 2022 $ / shares shares
Stockholders’ Equity (Details) [Line Items]
Common stock authorized	100,000,000	100,000,000
Common shares of par value (in Dollars per share) \| $ / shares	$ 0.001	$ 0.001
Common stock shares issued	11,364,903	11,267,389
Common stock, shares outstanding	11,364,903	11,267,389
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred shares of par value (in Dollars per share) \| $ / shares	$ 0.001	$ 0.001
Conversion price per share (in Dollars per share) \| $ / shares	$ 7.01
Common Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Voting rights	one
Series 1 Convertible Preferred Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred stock, shares authorized	8,028
Preferred stock, shares issued	7,991	8,027
Preferred stock, shares outstanding	7,991	8,027
Preferred stock convertible conversion ratio	1,000
Converted share of common stock	35,823
Series 1 Convertible Preferred Stock [Member] \| Common Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Preferred shares redeemed during conversion	36

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Jan. 01, 2023	Oct. 03, 2014
Stock-Based Compensation (Details) [Line Items]
Common stock shares issued	11,364,903		11,267,389
Weighted average grant date fair value per share (in Dollars per share)	$ 3.04
2020 Inducement Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Authorized for issuance of common stock under plan	600,000
Shares available for issuance	160,625
2017 Equity Incentive Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Shares available for issuance	2,000,000
Amended and Restated 2014 Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Shares available for issuance	544,137
2014 Employee Stock Purchase Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Authorized for issuance of common stock under plan					3,513
2014 Employee Stock Purchase Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Authorized for issuance of common stock under plan	39,087
Employee stock purchase plan increase descriptions	The number of shares increases each January 1, commencing on January 1, 2015 and ending on (and including) January 1, 2024, by an amount equal to the lesser of one percent of the outstanding shares as of the end of the immediately preceding fiscal year, 7,025 shares or any lower amount determined by the Company’s Board of Directors prior to each such January 1st.
Number of shares authorized	39,087
Minimum [Member] \| Amended and Restated 2014 Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Number of shares authorized and increased				861,933
Minimum [Member] \| 2014 Employee Stock Purchase Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Number of shares authorized and increased				7,025
Maximum [Member] \| Amended and Restated 2014 Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Number of shares authorized and increased				3,563,303
Maximum [Member] \| 2014 Employee Stock Purchase Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Number of shares authorized and increased				39,087
Restricted Stock Units (RSUs) [Member]
Stock-Based Compensation (Details) [Line Items]
Unamortized value of RSUs (in Dollars)	$ 863
Weighted average remaining amortization period	1 year 9 months 18 days
Number of RSUs	289,500		289,500
Common stock shares issued	61,691
Number of RSUs vested	94,528
Net share settlement (in Dollars)	$ 91
Weighted average grant date fair value per share (in Dollars per share)	$ 3.02
Stock Options [Member]
Stock-Based Compensation (Details) [Line Items]
Weighted average grant date fair value per share (in Dollars per share)	$ 2.4	$ 5.04
Unrecognized share based compensation for unvested stock option grants value (in Dollars)	$ 6,819
Recognized over a weighted average period	2 years 8 months 23 days

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of Restricted Stock Unit - Restricted stock unit [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Stock-Based Compensation (Details) - Schedule of Restricted Stock Unit [Line Items]
Non-vested Restricted Stock Units, Balance at beginning \| shares	196,838
Non-vested Weighted Average Grant Date Fair Value, Balance at beginning \| $ / shares	$ 12.49
Granted ,Restricted Stock Units \| shares	165,100
Granted ,Weighted Average Grant Date Fair Value \| $ / shares	$ 3.02
Forfeited ,Restricted Stock Units \| shares	(30,431)
Forfeited ,Weighted Average Grant Date Fair Value \| $ / shares	$ 4.36
Vested, Restricted Stock Units \| shares	(94,528)
Vested ,Weighted Average Grant Date Fair Value \| $ / shares	$ 12.16
Non-vested Restricted Stock Units, Balance at ending \| shares	236,979
Non-vested Weighted Average Grant Date Fair Value, Balance at ending \| $ / shares	$ 7.07

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of Stock Option Activities	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
Stock-Based Compensation (Details) - Schedule of Stock Option Activities [Line Items]
Weighted Average Exercise Price, Outstanding Beginning balance \| $ / shares	$ 14.23
Weighted Average Remaining Contractual Term (years), Outstanding Beginning balance	8 years 1 month 28 days
Aggregate Intrinsic Value, Outstanding Beginning balance \| $
Weighted Average Exercise Price, Outstanding Ending balance \| $ / shares	$ 9.77
Weighted Average Remaining Contractual Term (years), Outstanding Ending balance	8 years 18 days
Weighted Average Exercise Price, Vested and expected to vest \| $ / shares	$ 9.77
Weighted Average Remaining Contractual Term (years), Vested and expected to vest	8 years 18 days
Aggregate Intrinsic Value, Vested and expected to vest \| $
Weighted Average Exercise Price, Exercisable \| $ / shares	$ 15.93
Weighted Average Remaining Contractual Term (years), Exercisable	6 years 9 months 21 days
Aggregate Intrinsic Value, Exercisable \| $
Weighted Average Exercise Price, Granted \| $ / shares	$ 3.04
Aggregate Intrinsic Value, Granted \| $
Weighted Average Exercise Price, Exercised \| $ / shares
Aggregate Intrinsic Value, Exercised \| $
Weighted Average Exercise Price, Forfeited \| $ / shares	$ 6.93
Aggregate Intrinsic Value, Forfeited \| $
Weighted Average Exercise Price, Expired \| $ / shares	$ 14.39
Aggregate Intrinsic Value, Expired \| $
Equity Option [Member]
Stock-Based Compensation (Details) - Schedule of Stock Option Activities [Line Items]
Number of Options, Outstanding Beginning balance \| shares	1,828,329
Number of Options, Outstanding Ending balance \| shares	2,933,525
Number of Options, Vested and expected to vest \| shares	2,933,525
Number of Options, Exercisable \| shares	1,198,035
Number of Options, Granted \| shares	1,267,900
Number of Options, Exercised \| shares
Number of Options, Forfeited \| shares	(153,650)
Number of Options, Expired \| shares	(9,054)

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details) - Schedule of Total Stock Based Compensation Costs - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Schedule Of Total Stock Based Compensation Costs Abstract
Restricted stock units	$ 275	$ 287	$ 915	$ 991
Stock options	1,172	1,150	3,725	4,267
Total	$ 1,447	$ 1,437	$ 4,640	$ 5,258

Stock-Based Compensation (Det_5

Stock-Based Compensation (Details) - Schedule of Stock Based Compensation Expense - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 1,447	$ 1,437	$ 4,640	$ 5,258
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	419	361	1,233	1,150
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 1,028	$ 1,076	$ 3,407	$ 4,108

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - Schedule of Net Loss Per Share Attributable to Common Stockholders, Basic and Diluted - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Numerator:
Net loss attributable to common stockholders	$ (9,860)	$ (7,691)	$ (30,199)	$ (26,985)
Denominator:
Weighted-average shares of common stock outstanding, basic	11,347,887	11,265,475	11,320,027	11,256,995
Net loss per share attributable to common stockholders, basic	$ (0.87)	$ (0.68)	$ (2.67)	$ (2.4)

Net Loss Per Common Share (De_2

Net Loss Per Common Share (Details) - Schedule of Net Loss Per Share Attributable to Common Stockholders, Basic and Diluted (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Schedule of Net Loss Per Share Attributable to Common Stockholders Basic and Diluted [Abstract]
Weighted-average shares of common stock outstanding, diluted	11,347,887	11,265,475	11,320,027	11,256,995
Net loss per share attributable to common stockholders, diluted	$ (0.87)	$ (0.68)	$ (2.67)	$ (2.40)

Net Loss Per Common Share (De_3

Net Loss Per Common Share (Details) - Schedule of Weighted Average Dilutive Common Shares - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Net Loss Per Common Share (Details) - Schedule of Weighted Average Dilutive Common Shares [Line Items]
Total potentially dilutive shares	11,453,221	10,385,335
Stock options issued and outstanding [Member]
Net Loss Per Common Share (Details) - Schedule of Weighted Average Dilutive Common Shares [Line Items]
Total potentially dilutive shares	2,933,525	1,862,358
Restricted stock units issued and outstanding [Member]
Net Loss Per Common Share (Details) - Schedule of Weighted Average Dilutive Common Shares [Line Items]
Total potentially dilutive shares	526,479	493,938
Conversion of Series 1 Convertible Preferred Stock [Member]
Net Loss Per Common Share (Details) - Schedule of Weighted Average Dilutive Common Shares [Line Items]
Total potentially dilutive shares	7,993,217	8,029,039